Wells Fargo Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $6
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Brandon Couillard maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $6.5 to $6.
Wells Fargo analyst Brandon Couillard maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $6.5 to $6.